Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crescita TherapeuticsTSX:CTX 20 FCF Margin % is 2.20% as of Mar. 2026. GuruFocus rates TSX:CTX with a GF Score™ of 20/100. The stock has 5 warning signs investors should review. Among 960 Drug Manufacturers companies, Crescita Therapeutics ranks better than 60.42% on this metric.
Crescita Therapeutics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Crescita Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescita Therapeutics FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Crescita Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crescita Therapeutics (TSX:CTX) has a FCF Margin % of 2.20% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Crescita Therapeutics and its competitors. According to the industry distribution chart, Crescita Therapeutics ranks #380 out of 960 companies in the Drug Manufacturers industry, placing it in the top 39.6%.
Is Crescita Therapeutics' FCF Margin % too high?
Crescita Therapeutics' current FCF Margin % is 2.20%. The Drug Manufacturers industry median FCF Margin % is 2.44. Crescita Therapeutics' value of 2.20% is 9.8% below this industry median. Based on the distribution chart, Crescita Therapeutics ranks #380 out of 960 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Crescita Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Crescita Therapeutics ranks #380 out of 960 companies for FCF Margin %. This puts Crescita Therapeutics in the upper half of its industry. The industry median FCF Margin % is 2.44. Crescita Therapeutics' value of 2.20% is 9.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.44, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crescita Therapeutics's current FCF Margin % of 2.20% is 9.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Crescita Therapeutics and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crescita Therapeutics's current FCF Margin % is 2.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Crescita Therapeutics (TSX:CTX) has a current FCF Margin % of 2.20%. The current FCF Margin % is 2.20% and 9.8% below the Drug Manufacturers industry median of 2.44. Crescita Therapeutics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Crescita Therapeutics (TSX:CTX), the current FCF Margin % is 2.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
20GF Score
Get the complete analysis for TSX:CTX
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:CTX has been successfully added to your 
